Study of Cretostimogene for non-muscle invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new drug, Cretostimogene, for people with a type of bladder cancer that hasn't spread into the muscle layer (non-muscle invasive) and has not responded to standard BCG treatment. The goal is to see if this drug can help control the cancer and avoid the need for bladder removal surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have bladder cancer that has not spread into the muscle layer (non-muscle invasive) and includes a type called carcinoma in situ (CIS), with or without other papillary tumors
- Your cancer has not responded to BCG treatment (BCG-unresponsive)
- You are not able to have or have chosen not to have surgery to remove your bladder (radical cystectomy)
- You are willing to have regular bladder exams (cystoscopies), urine tests, and biopsies as part of the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with bladder cancer that has not responded to BCG therapy. The study tests a new virus-based treatment (called cretostimogene grenadenorepvec) that is given directly into the bladder to help fight the cancer cells.
This trial tests a new study medicine called PF-08052667 for people with a certain type of bladder cancer that hasn't spread into the muscle. It's for those who have already tried BCG treatment and can't or won't have their bladder removed.
This Phase 2 trial tests TARA-002 given directly into the bladder to treat high-grade non–muscle-invasive bladder cancer with active disease. It may help patients who have not previously responded to, or have not received, BCG treatment in the recent past.
This trial tests a new treatment called NDV01 KIT for people with high-grade non-muscle invasive bladder cancer that hasn't gotten better after BCG therapy. It's for those who cannot or choose not to have their bladder removed.
This study tests an immunotherapy drug (toripalimab) alone or followed by medication placed directly into the bladder (gemcitabine and mitomycin C) for people with high-risk bladder cancer that has not spread into the muscle wall and that has not responded to or couldn't be handled with BCG therapy. The goal is to see which approach works better.
This trial tests a new drug, 2141-V11, for people with bladder cancer that has not gone away after standard treatments like BCG therapy. It may help those with non-muscle invasive bladder cancer or, in one group, muscle-invasive bladder cancer, who cannot have or choose not to have bladder removal surgery.
Hear when a new Non Muscle Invasive Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.